PDS Biotechnology
PDSB
31 hedge funds and large institutions have $7.68M invested in PDS Biotechnology in 2020 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 6 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
125% more capital invested
Capital invested by funds: $3.42M → $7.68M (+$4.26M)
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
24% more funds holding
Funds holding: 25 → 31 (+6)
3.73% more ownership
Funds ownership: 11.09% → 14.82% (+3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.6M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.18M |
| 3 |
IWA
Inspirion Wealth Advisors
Libertyville,
Illinois
|
+$578K |
| 4 |
Renaissance Technologies
New York
|
+$452K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$290K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$66K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$20K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$1K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$137 |
| 5 |
TI
tru Independence
Portland,
Oregon
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
26
Chiron Capital Management
Tallahassee,
Florida
| $1K | +$1.4K | +500 | New |
|
|
FDCDDQ
27
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $58 | +$70 | +25 | New |
|
|
28
Two Sigma Advisers
New York
| – | -$66K | -32,800 | Closed |
|
|
WS
29
Wedbush Securities
Los Angeles,
California
| – | -$20K | -10,000 | Closed |
|
|
TI
30
tru Independence
Portland,
Oregon
| – | -$1 | -500 | Closed |
|
|
31
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$1K | -300 | Closed |
|
|
PFS
32
Prospera Financial Services
Dallas,
Texas
| – | +$280 | +100 | New |
|
PDSB Hedge Fund Activity: Q3 2020 in Review
31 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2020, worth a combined $7.68M — up 125% from $3.42M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PDSB positions and 6 closed out — a net gain of 6 holders — while 7 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.6M. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $66K sold.
- 31 institutional investors held PDS Biotechnology (PDSB) as of Q3 2020, up from 25 in Q2 2020.
- Funds reported $7.68M of PDS Biotechnology stock for Q3 2020, up 125% quarter-over-quarter.
- 12 funds opened new PDS Biotechnology positions in Q3 2020 and 6 closed out, a net change of +6 holders.
- The largest PDS Biotechnology buyer in Q3 2020 was Vanguard Group, an estimated $1.6M added.
- The largest PDS Biotechnology seller in Q3 2020 was Two Sigma Advisers, an estimated $66K sold.
Based on aggregated 13F filings for Q3 2020.